- Home
- HHS vs VYNE Comparison
HHS vs VYNE Comparison
Compare HHS & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HHS | VYNE |
|---|---|---|
| Founded | 1923 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2M | 20.0M |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HHS | VYNE |
|---|---|---|
| Price | $2.86 | $0.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.3K | ★ 323.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,242,000.00 | N/A |
| Revenue This Year | $6.54 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.33 | $0.29 |
| 52 Week High | $5.39 | $2.05 |
Technical Indicators
Market Signals| Indicator | HHS | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 54.69 |
| Support Level | $2.33 | $0.55 |
| Resistance Level | $3.03 | $0.60 |
| Average True Range (ATR) | 0.08 | 0.02 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 0.00 | 56.07 |
Price Performance
Historical ComparisonAbout HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.